A carregar...

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?

PURPOSE: To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. METHODS: Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ghazi, Nicola G, Kirk, Tyler Q, Knape, Robert M, Tiedeman, James S, Conway, Brian P
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2861937/
https://ncbi.nlm.nih.gov/pubmed/20463798
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!